Axsome Therapeutics, Inc.NASDAQ: AXSM

Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder

· Issued by Axsome Therapeutics, Inc.

On 6ix: 6ix.com/news/axsome-therapeutics-presents-new-data-from-gemini-phase-3-trial-with-axs-05

Watch Axsome Therapeutics' latest callAxsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings Call · Replay · Aug 10Read the transcript of Axsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings Call
Axsome Therapeutics' next earnings callAxsome Therapeutics (NASDAQ:AXSM) Q3 2026 Earnings Call · Nov 2, 2026 at 8:00 AM ESTRegister

Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001)

Clinical response on the QIDS-SR-16 demonstrated in 53% of patients with AXS-05 compared to 33% for placebo (p

Axsome Therapeutics, Inc. on 6ix

In the deck

Story so far

Earlier from Axsome Therapeutics

Later from Axsome Therapeutics

All Axsome Therapeutics news releases